Typhoid-tetanus toxoid conjugate vaccine - Cadila HealthcareAlternative Names: Tetanus-typhoid toxoid conjugate vaccine - Cadila; Typhoid Vi capsular polysaccharide tetanus toxoid conjugate vaccine; Vi Capsular polysaccharide vaccine - Cadila
Latest Information Update: 28 Sep 2016
At a glance
- Originator Cadila Healthcare
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Tetanus; Typhoid
Most Recent Events
- 24 Apr 2015 Phase-I clinical trials in Tetanus (In adults, In volunteers) in India (IM) (CTRI2015-04-005710)
- 24 Apr 2015 Phase-I clinical trials in Typhoid (In adults, In volunteers) in India (IM) (CTRI2015-04-005710)